Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Ruxolitinib + Chemotherapy in AYAs With Ph-like ALL
NCT03571321Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- May 2019
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in acute lymphoblastic leukemia (ALL), sponsored by University of Chicago. Primary endpoint: Feasibility of adding ruxolitinib to a standard-of-care pediatric-based chemotherapy regimen at 24 weeks. Started May 2019; status: recruiting.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03571321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571321.